"10.1371_journal.pone.0140877","plos one","2015-12-07T00:00:00Z","Cristina Mussini; Patrizia Lorenzini; Massimo Puoti; Miriam Lichtner; Giuseppe Lapadula; Simona Di Giambenedetto; Andrea Antinori; Giordano Madeddu; Alessandro Cozzi-Lepri; Antonella d’Arminio Monforte; Andrea De Luca; ICONA Foundation study group","Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy; National Institute for Infectious Diseases L. Spallanzani, Rome, Italy; Clinic of Infectious Diseases, Maggiore Hospital, Milan, Italy; Clinic of Infectious Diseases, La Sapienza University, Rome, Italy; Department of Infectious Diseases, San Gerardo Hospital, Monza, Italy; Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy; Clinica delle Malattie Infettive, Università di Sassari, Sassari, Italy; Department of Infection & Population Health Division of Population Health, Hampstead Campus, University College London, London, United Kingdom; Clinic of Infectious Diseases, Department of Health Sciences, San Paolo Hospital, Milan, Italy; Division of Infectious Diseases, Department of Medical Biotechnologies, University of Siena and Siena University Hospital, Siena, Italy","Conceived and designed the experiments: CM ADL. Performed the experiments: ADL CM MP AdM. Analyzed the data: PL ACL ADL CM MP AdM. Contributed reagents/materials/analysis tools: CM MP AdM ML GL SDG AA GM. Wrote the paper: ADL CM MP AdM PL ACL. Revised the manuscript giving relevant intellectual contribution to its content: ADL CM MP AdM PL ACL ML GL SDG AA GM.","CM declares to be member of boards for Gilead, BMS, ViiV, Abbvie, MSD and have been member of speakers bureau for Gilead. MP declares consultancies for Bristol-Myers Squibb, ViiV, Gilead, Abbvie, Merck Sharp and Dohme, grants from Gilead Sciences, ViiV and Bristol-Myers Squibb and payment for lectures from Bristol-Myers Squibb, ViiV, GSK, Gilead, Abbvie, Merck Sharp and Dohme and Janssen. ML declares board membership for Gilead, Abbvie, has received grants from Gilead and payment for lectures from Bristol, Merck. GL declares board membership for Gilead, has received grants from Gilead, payment for lectures including service on speakers bureau from Gilead, BMS, Abbvie, Janssen-Cilag and travel grants from Gilead Sciences, Merck, Abbvie. SDG declares to have been member of boards for ViiV, BMS, Janssen Cilag, Abbott, Merck, Gilead. AA reports consultancies for Bristol-Myers Squibb, ViiV, Gilead, Abbvie, Merck Sharp and Dohme and Janssen-Cilag, grants from Gilead Sciences, Janssen-Cilag and Bristol-Myers Squibb and travel grants from Abbvie. GM reports board membership for ViiV and membership of speakers bureau for Gilead Sciences. ACL is employed by the ICONA Foundation. AdAM declares to have been member of boards for Abbvie, BMS, Gilead, Janssen, ViiV, MSD. ADL declares board membership for Gilead and ViiV, consultancies for Abbvie, Merck, Teva and Janssen, grants from ViiV and Merck, service in speakerss bureau for Gilead and travel grants from ViiV and Janssen. PL declares that no competing interests exist. The ICONA Foundation Study is sponsored by unrestricted grants from Abbvie Italy, Bristol-Myers Squibb Italy, Gilead Italy, Janssen Italy, ViiV Healthcare Italy. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","12","Cristina Mussini","CM",12,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA
